Guardant Health (GH)
NASDAQ:GH
Want to see GH full AI Analyst Report?
GH Stock Chart & Stats
$90.36
$0.91(2.52%)
At close: 4:00 PM EST
$90.36
$0.91(2.52%)
Day’s Range― - ―
52-Week Range$36.36 - $120.74
Previous CloseN/A
Volume639.07K
Average Volume (3M)1.99M
Market Cap
$11.96B
Enterprise Value$13.05B
Total Cash (Recent Filing)$1.20B
Total Debt (Recent Filing)$1.68B
Price to Earnings (P/E)―
Beta1.37
Next Earnings
May 07, 2026EPS Estimate
-0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.31
Shares Outstanding131,170,440
10 Day Avg. Volume2,409,980
30 Day Avg. Volume1,993,401
Financial Highlights & Ratios
PEG Ratio4.56
Price to Book (P/B)-128.95
Price to Sales (P/S)13.04
P/FCF Ratio-54.94
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue13.29
Enterprise Value/Gross Profit20.61
Enterprise Value/Ebitda-34.89
Forecast
1Y Price Target
$128.83Price Target Upside42.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
EPS Forecast (FY)-2.96
Revenue Forecast (FY)$1.27B
Bulls Say, Bears Say
Bulls Say
Clinical Trial ValidationSERENA-6 results could drive greater use of Guardant360 CDx in a subgroup of breast cancer patients and help establish ctDNA as a practical tool for earlier detection of genomic changes that inform treatment choices.
MRD Coverage And Oncology MomentumExpanded Medicare coverage for minimal residual disease testing alongside steady oncology testing growth could strengthen revenue momentum and improve the trajectory toward cash flow breakeven.
Screening AdoptionFaster-than-expected adoption of the Shield colorectal screening test, supported by an expanded salesforce and strong patient adherence, could expand screening volumes and create a recurring revenue stream.
Bears Say
Financial SustainabilityOngoing operating losses and sustained cash burn highlight uncertainty about the path to sustained profitability and increase the risk of future financing needs or dilution.
Trial Performance ConcernsLower-than-anticipated sensitivity in a pivotal trial and a separate multi-cancer study missing its endpoint raise doubts about screening test performance and could slow clinical adoption.
Valuation And Execution RiskA rotation away from high-growth diagnostic names, mixed revenue quality and analyst reservations about Shield's long-term market share create valuation pressure and elevate execution risk for the company.
Guardant Health News
GH FAQ
What was Guardant Health’s price range in the past 12 months?
Guardant Health lowest stock price was $36.36 and its highest was $120.74 in the past 12 months.
What is Guardant Health’s market cap?
Guardant Health’s market cap is $11.96B.
When is Guardant Health’s upcoming earnings report date?
Guardant Health’s upcoming earnings report date is May 07, 2026 which is today.
How were Guardant Health’s earnings last quarter?
Guardant Health released its earnings results on Feb 19, 2026. The company reported -$1 earnings per share for the quarter, missing the consensus estimate of -$0.767 by -$0.233.
Is Guardant Health overvalued?
According to Wall Street analysts Guardant Health’s price is currently Undervalued.
Does Guardant Health pay dividends?
Guardant Health does not currently pay dividends.
What is Guardant Health’s EPS estimate?
Guardant Health’s EPS estimate is -0.81.
How many shares outstanding does Guardant Health have?
Guardant Health has 131,170,440 shares outstanding.
What happened to Guardant Health’s price movement after its last earnings report?
Guardant Health reported an EPS of -$1 in its last earnings report, missing expectations of -$0.767. Following the earnings report the stock price went down -3.083%.
Which hedge fund is a major shareholder of Guardant Health?
Currently, no hedge funds are holding shares in GH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Guardant Health Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$128.83 (42.58% Upside)
$128.83 (42.58% Upside)
Blogger Sentiment
Bullish
GH Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 227.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 2.7%
Last 30 Days ▲ 2.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
100.93%
12-Months-Change
Fundamentals
Return on Equity
164.85%
Trailing 12-Months
Asset Growth
35.54%
Trailing 12-Months
Company Description
Guardant Health
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.
GH Company Deck
GH Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a largely positive growth and execution story: strong revenue and volume growth across oncology and screening, improved gross margins and reduced per-test costs (notably for Reveal), meaningful commercial traction for Shield (high adherence, ADLT reimbursement, EMR integrations, Quest/PathGroup partnerships), and improved profitability trends with a solid cash runway. At the same time, significant near-term investments—primarily in Shield—continue to drive company-wide cash burn and operating expenses, and several important upside catalysts (FDA approvals, additional reimbursements, co-promotion benefits) remain uncertain and are not included in the base guidance. Overall the company is growing rapidly with improving margins and clearer path to profitability, but execution and reimbursement risks and continued screening-related cash burn temper the near-term financial picture.View all GH earnings summariesGH Revenue Breakdown
91.19% Precision oncology testing
8.81% Development services and other
GH Stock 12 Month Forecast
Average Price Target
$128.83
▲(42.58% Upside)
Technical Analysis
Ownership Overview
3.62% Insiders
31.96% Mutual Funds
2.39% Other Institutional Investors
46.25% Public Companies and
Individual Investors